Obesity Featured Articles

  1. The Case For Research-Naive PIs 1/9/2026

    Carrie Lewis, executive director, clinical program optimization, at Keenova (formerly Endo) explains why research-naive PIs may improve trial quality, challenge assumptions about ROI, and help fix a shrinking investigator pipeline.

  2. Making Medical Innovation Matter To Patients With Simplified Trial Design 1/9/2026

    To be a leader in today’s environment, Lexicon Pharmaceuticals CMO Craig Granowitz, MD, Ph.D., says companies must embrace simplified clinical trial designs, which can reduce regulatory risks, lower R&D costs, and shorten clinical timelines.

  3. Build Or Buy: Adopting AI Agents In Life Sciences 1/8/2026

    Should your team build custom AI agents from scratch or partner with a ready-made solution? This practical guide cuts through the hype to reveal the strategic insights you need.

  4. Agentic AI Is Transforming Life Sciences Discovery And Operations 1/8/2026

    73% of pharma companies are planning or deploying agentic AI. Discover who’s leading and how intelligent agents are transforming R&D.

  5. FDA Pushes For Patient Voice: ePRO In Oncology Trials 1/8/2026

    FDA urges sponsors and CROs to include patient voices in oncology trials. Discover why it matters and how to start integrating this approach.

  6. How A Strategic Bioanalysis CRO Partnership Empowers Sponsors 1/8/2026

    Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

  7. How Should Scientific Focus Change In 2026? Researchers Weigh In 1/8/2026

    To kick off 2026, clinical researchers share how they think research should change in the new year.

  8. 6 Key Implications Of EU Clinical Trials Regulation 1/7/2026

    Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

  9. Researchers Want A Design Shake-Up In 2026 1/7/2026

    When asked what clinical research professionals should leave behind in 2025, quite a few lamented the stale, even problematic, approach to clinical trial design. Here's what they want done differently in 2026.

  10. Meeting Your Clinical Trial Enrollment Target Without Delays 1/6/2026

    Bridge the enrollment gap by blending site-based tactics with global direct-to-patient outreach. Use digital screening and EMR intelligence to ensure faster, more predictable paths to randomization.